Jeffry P. Simko, PhD, MD

Jeffry P. Simko, PhD, MD

Professor of Clinical Pathology, Departments of Anatomic Pathology, Urology and Radiation Oncology
Pathology
Division
Surgical Pathology
Specialty Areas
Surgical Pathology
Prostate
Bladder Tumor
Kidney Tumor
Genitourinary Pathology
Research

UCSF
Pathology, Box 4066
1825 4th Street, Room M2360
San Francisco, CA 94143
United States

Hospital Affiliations
UCSF Mission Bay
Other UCSF Organizational Association(s)
  • Professor of Clinical Pathology, Departments of Urology and Radiation Oncology
  • Director, Genitourinary Program Tissue Core, UCSF Helen Diller Family Comprehensive Cancer Center
  • Director, NRG Biobank (An NCI Sponsored National Cooperative Group Resource)
  • Director, Genitourinary Pathology Fellowship Program
  • Principal Investigator, UCSF Prostate SPORE Prostate Tissue Core
Research and Clinical Interests

My mission within the Department of Pathology is fourfold. My major focus is genitourinary pathology, where I closely interact with the urologic oncology group of the UCSF Comprehensive Cancer Center concerning clinical and basic science problems. A large number of research projects amenable to resident participation are available in this area. Specific areas include radiologic-pathologic correlation studies and imaging technology development (mainly focused on MRI/MRSI of the prostate and kidney), biomarker discovery efforts, clinical-pathologic correlation studies, and tumor model construction and characterization. These efforts also extend to my participation in some of the cooperative groups performing national clinical trials (NRG and "The Alliance"). I also participate in biospecimen banking efforts here at UCSF, and on a national level through participation in the NRG, one of the NCI-sponsored cooperative groups performing international clinical trials related to cancer treatment. I also perform general surgical pathology sign out and molecular pathology signout duties.

For additional information, please link to:

Selected Publications
  • Starobinets O, Simko JP, Gibbons M, Kurhanewicz J, Carroll PR, Noworolski SM. The impact of benign tissue within cancerous regions in the prostate: Characterizing sparse and dense prostate cancers on whole-mount histopathology and on multiparametric MRI. Magn Reson Imaging. 2024 Sep 10;114:110233. doi: 10.1016/j.mri.2024.110233. Epub ahead of print. PMID: 39260625.
  • Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology. 2024 Oct;85(4):598-613. doi: 10.1111/his.15231. Epub 2024 Jun 3. PMID: 38828674; PMCID: PMC11365761.
  • Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023 Aug;2(8):EVIDoa2300023. doi: 10.1056/EVIDoa2300023. Epub 2023 Jun 29. PMID: 38320143; PMCID: PMC11195914.
  • Nguyen HG, van den Berg NS, Antaris AL, Xue L, Greenberg S, Rosenthal JW, Muchnik A, Klaassen A, Simko JP, Dutta S, Sorger JM, Munster P, Carroll PR. First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy. Eur Urol Oncol. 2024 Feb;7(1):63-72. doi: 10.1016/j.euo.2023.07.004. Epub 2023 Jul 27. PMID: 37516587.
  • Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY, Mohamad O. Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2023 Feb 22;6(1):27. doi: 10.1038/s41746-023-00769-z. Erratum for: NPJ Digit Med. 2022 Jun 8;5(1):71. doi: 10.1038/s41746-022-00613-w. PMID: 36813827; PMCID: PMC9947124.
  • Paner GP, Zhou M, Simko JP, Eggener SE, van der Kwast T. Renaming Grade Group 1 Prostate "Cancer" From a Pathology Perspective: A Call for Multidisciplinary Discussion. Adv Anat Pathol. 2023 Apr 17. doi: 10.1097/PAP.0000000000000400. Epub ahead of print. PMID: 37072903.
Additional Information